The Clinical Pipeline - a new column from Nature Medicine

Our new fortnightly column will analyse the latest in translational and clinical research, from bench to bedside
Published in Healthcare & Nursing
The Clinical Pipeline - a new column from Nature Medicine

Share this post

Choose a social network to share with, or copy the shortened URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

This week Nature Medicine published the third in a new fortnightly column called The Clinical Pipeline.

Our goal is to further strengthen the journal's coverage of translational and clinical research, from bench to bedside, and so each column will analyse a recent clinical trial announcement, preprint, or journal publication (with all the caveats that apply to non-peer reviewed research!)

Thiago Carvalho is writing these articles for us, as an experienced Nature Medicine freelancer and author of our COVID Research in Brief articles during the pandemic.

Thiago's first column covered BioNTech’s new combination mRNA / CAR-T cancer vaccine; the second column discussed the unknown efficacy of the antiviral, tecovirimat, against monkeypox; and today's column covers how the FDA are using biomarker data in the approval of new drugs for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.

This is something of an experiment for the journal, so please let us know if you found them interesting and/or useful - or any other feedback!

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Follow the Topic

Health Care
Life Sciences > Health Sciences > Health Care
  • Nature Medicine Nature Medicine

    This journal encompasses original research ranging from new concepts in human biology and disease pathogenesis to new therapeutic modalities and drug development, to all phases of clinical work, as well as innovative technologies aimed at improving human health.